Skip to main content

Table 5 Candidate genes involved in phenotypic response to afatinib treatment

From: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

a) Genes potentially involved in reduction of motility after afatinib treatment
SERPINE1
HBEGF
F3
ITGA2
CXCL8
HAS2
PLPP3
SPRY2
F2RL1 PTGS2 CYR61 CXCL1 SEMA6D ETS1
b) Genes potentially involved in induction of apoptosis after afatinib treatment
BAX BBC3 BCLAF1 CAV1 E2F1 FADD FAF1 FAS GSN HYAL2
IL19 IL20RA INHBB LCK LGALS9 NACC2 NF1 NFATC4 NKX3-1 PAK2
PARK7 PDCD5 PDIA3 PEA15 PPIF PPP2R1B PPP3CC PRKRA SFN SFPQ
SKIL SLC9A3R1 SMAD3 STK4 TGFBR1 TP73 TPD52L1 YWHAB YWHAE YWHAG
YWHAH YWHAQ YWHAZ ZNF205       
  1. Genes that were regulated in MKN1 cells after 4 h afatinib and trastuzumab + afatinib treatment and were assigned to the biological function “positive regulation of cell motility” were selected (a). Genes that were regulated in NCI-N87 but not in MKN1 and MKN7 cells after 24 h afatinib and trastuzumab + afatinib treatment and were assigned to the biological function “positive regulation of apoptotic signaling pathway” were selected (b). Italics typeface indicates downregulation and bold typeface upregulation
\